Xilio Therapeutics Inc
XLO
View Detailed Chart
0.541USD
+0.021+4.04%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
28.03MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.04%
5 Days
-9.08%
1 Month
-22.18%
6 Months
-18.07%
Year to Date
-15.51%
1 Year
-21.61%
View Detailed Chart
TradingKey Stock Score of Xilio Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Xilio Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 67 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 2.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Xilio Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Xilio Therapeutics Inc Highlights
StrengthsRisks
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.34M.
Fairly Valued
The company’s latest PE is -0.88, at a medium 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 204.70K shares of this stock.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
2.000
Target Price
+284.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Xilio Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Xilio Therapeutics Inc Info
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Ticker SymbolXLO
CompanyXilio Therapeutics Inc
CEORusso (Rene)
Websitehttps://xiliotx.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69226.520
-743.610 (-1.06%)
282.580
+22.390 (+8.61%)
2066.090
+14.360 (+0.70%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
